Related Experiment Videos
Platelet-activating factor (PAF) does not affect diastolic function in isolated rat hearts
H R Muñoz1, R D Evans, S C Marsch
1Nuffield Department of Anaesthetics, Radcliffe Infirmary, Oxford, UK.
Insights
Platelet-activating factor (PAF) did not directly cause diastolic dysfunction in isolated rat hearts. Studies showed PAF decreased heart contractility but did not significantly alter relaxation or stiffness.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Cardiac Diastolic Function
Background:
- Diastolic dysfunction is implicated in various disease states.
- Platelet-activating factor (PAF) is a potential mediator of cardiovascular alterations.
- The direct impact of PAF on diastolic function remains understudied.
Purpose of the Study:
- To investigate the direct effects of platelet-activating factor (PAF) on cardiac diastolic function.
- To determine if PAF contributes to diastolic dysfunction in an isolated perfused rat heart model.
Main Methods:
- Isolated perfused rat hearts were exposed to incremental concentrations of PAF (up to 200 nM).
- Measurements included coronary flow rate, contractility (peak +dP/dt), and diastolic parameters (time constant of relaxation, chamber stiffness constant).
- Comparisons were made against baseline and vehicle-administered controls.
Main Results:
- PAF significantly decreased coronary flow rate and contractility in a dose-dependent manner.
- High-dose PAF showed a non-significant decrease in peak -dP/dt compared to controls.
- No significant changes were observed in the time constant of left ventricular relaxation or the chamber stiffness constant.
Conclusions:
- The study's findings do not support a major direct role for PAF in causing diastolic dysfunction.
- PAF's primary effects in this model were on coronary flow and contractility, not diastolic relaxation or stiffness.
- Further research may explore indirect mechanisms or different experimental conditions.
Abstract:
Platelet-activating factor might be responsible for the alterations of diastolic function observed in different disease states and these potential effects have not been studied. The effect of incremental concentrations of platelet-activating factor (to a maximum of 200 nM) was therefore examined in isolated perfused rat heart. Platelet-activating factor decreased coronary flow rate and contractility in a dose-dependent manner. Although high-dose platelet-activating factor decreased peak -dP/dt compared to baseline, this was not significant when compared to vehicle-administered control. There were no changes in the time constant of left ventricular relaxation and the chamber stiffness constant. These results do not support a major direct role of platelet-activating factor in diastolic dysfunction.